Previous studies have reported that IGF II was expressed at a moderate to high level in 43–57% of breast cancers by in situ hybridization and by immunohistochemistry [17,42,43], with localization primarily to stromal fibroblasts or vessel walls [17,42], making IGF II a potential candidate to mediate fibroblast–epithelial interactions. Here, IGF2 is linked to breast cancer.